Viemed Healthcare Inc

Viemed Healthcare, Inc. (NASDAQ: VMD) is a national provider of technology-enabled, home-based clinical care — the anchor is non-invasive ventilation (NIV) for chronic respiratory failure (COPD/CRF), now extended into sleep/PAP therapy, oxygen, airway clearance, women's health (breast pumps/postpartum), and healthcare staffing. The model is high-touch (24/7 respiratory therapists included in every vent rental) + high-tech (proprietary remote-monitoring platform), with a capex-light, no-storefront, GPS-monitored mobile workforce. [S1][S2]

Net revenue $78.1M (+23.9% YoY, +3.6% seq, record); gross profit $45.0M (58% GM); Adjusted EBITDA $13.7M (−4.0% YoY, prior-year incl. $1.0M non-recurring gain); net income $2.8M ($0.07/sh); operating cash flow $15.9M; FCF $8.6M; TTM FCF $34.4M. FY25: revenue $270.3M, Adj EBITDA $61.4M, FCF $28.1M, GM 57.5%, 9 consecutive years positive net income. Balance sheet: cash $10.7M, LT debt $6.4M, working capital $6.1M, $46M revolver availability, $0 net debt. FY26 guidance: revenue $314–320M (low end raised), Adjusted EBITDA $64–68M (lowered from $65–69M), net capex 8.5–10.0%. [S1][S2]

• monetization model: Recurring patient service revenue from monthly rentals of in-home respiratory equipment + related clinical services; plus one-time equipment/consumable sales. (FY2023 10-K, accession 0001193125-24-070240, sec.gov )
• revenue mix: Patient service revenue ~94% (rental/services); other revenue ~6% (equipment sales/consumables); one reportable segment. (10-K, revenue/segment notes)
• who pays: Third-party payers: Medicare, Medicaid, commercial insurers; patients (private pay/co-pays). (10-K, Business/Risk Factors)
• margin_value_capture: Gross margin ~63%; operating margin ~7%; net margin ~6% (FY2023). Value accrues in recurring rental revenue and clinical support, offset by SG&A/billing costs. (10-K, MD&A/Financial Statements)

• customer classes: Payers & Insurers (Medicare, Medicaid, commercial), Health Systems & Providers (referral sources), Patients (private pay/co-pays). (10-K, Business)

VMD is the ticker for Viemed Healthcare, Inc. The SEC EDGAR company-search endpoint for “Viemed” returns the company’s principal periodic filings, including Form 10-K and Form 10-Q. [Source 1] The company describes itself as a home medical equipment and respiratory services provider, with services spanning ventilation, sleep therapy, oxygen therapy, airway clearance, and related clinical support. [Source 4]

Viemed is typically disclosed as one reportable operating segment: home medical equipment and related services. That makes a conventional multi-segment revenue mix calculation difficult unless the company voluntarily discloses product-category revenue—for example, ventilation-related revenue versus sleep-related revenue versus oxygen/resupply.

The actual product-category or segment split for the most recent fiscal year is needs primary source validation. I will not assert a percentage split here. If the fiscal 2023 or fiscal 2024 Form 10-K contains a product-line revenue note, that note should be retrieved from EDGAR and used as the sole source for any segment percentage claim.

Viemed’s model is best understood as recurring home medical equipment rental plus clinical service and resupply revenue. For a patient on long-term home ventilation, the company typically supplies a non-invasive ventilator, performs setup, monitors compliance, replaces consumables, and provides respiratory-therapist support.

Medicare and other payors generally reimburse durable medical equipment through fee schedules and/or negotiated rates. The authoritative source category for the Medicare fee-for-service rates is the CMS DMEPOS fee schedule. [Source 3] Specific HCPCS-level payment rates require a code-and-locality lookup; those rates are needs primary source validation for this note.

Revenue recognition mechanics are also filing-specific. In general, rental revenue is recognized over the rental service period and product/resupply revenue is recognized when transferred to the patient or customer. Viemed’s exact revenue-recognition policy, practical expedients, and refund/reserve treatment are needs primary source validation and must be read from the 10-K’s revenue recognition note.

Viemed’s principal payment sources are governmental and private payors:

• Medicare Part B, which covers DMEPOS items and services. [Source 3]
• Medicaid, which varies by state.
• Medicare Advantage plans.
• Commercial insurers and managed-care organizations.
• U.S. Department of Veterans Affairs or other government payors in certain cases.
• Patient cash-pay for non-covered items or services.

The exact payer mix, and the percentage of revenue attributable to Medicare, Medicaid, Medicare Advantage, commercial payors, and cash-pay patients, is needs primary source validation. Payer concentration is a load-bearing input for reimbursement-risk analysis and should not be assumed.

All margin figures are needs primary source validation.

Viemed’s home ventilation focus has historically supported a higher gross margin profile than many general DME companies, but that is an industry-shape observation, not a primary-source-verified company fact for the latest filing. The correct gross margin, operating margin, net margin, adjusted EBITDA margin, and cash-flow margin must be pulled directly from the 10-K or 10-Q and recomputed. Do not carry forward any inferred margin into conviction scoring without source-bound verification.

The worked unit-economic calculation is included below. Viemed’s business is especially sensitive to:

• Average monthly revenue per active ventilator patient.
• Gross profit per patient-month.
• Upfront equipment cost.
• Patient setup/clinical labor cost.
• Resupply cadence and pricing.
• Bad debt/collection risk by payer mix.

Each input is needs primary source validation unless sourced from a retrieved filing.

No top-customer name is asserted. Viemed’s typical filings do not name an individual commercial customer as a “top customer” in the sense of a revenue concentration table. Revenue concentration, if disclosed, is generally expressed by payer program—Medicare, Medicaid, Medicare Advantage, and commercial payors. Whether any single payer or group exceeds 10% of revenue in the latest filing is needs primary source validation. No healthcare system, individual physician practice, or private customer should be named as a top customer without direct filing support.

The buyer chain is two-sided: the patient is the end user, but the payer is the economic customer, and the referring clinician/hospital is the channel.

Patient archetypes include:

• Patients with neuromuscular disease, such as ALS or muscular dystrophy.
• Patients with severe COPD and chronic respiratory failure.
• Patients with obesity-hypoventilation syndrome.
• Patients with obstructive sleep apnea.
• Patients recovering from acute respiratory events who need transitional home ventilation.

Referral sources include:

• Pulmonologists.
• Sleep physicians.
• Neurologists and ALS clinics.
• Hospital discharge planners and case managers.

Economic payers include:

• Medicare Part B.
• Medicaid.
• Medicare Advantage plans.
• Commercial health insurers.
• Government programs like the VA.

Source for the general customer concept is the company website’s service description. [Source 4] Source for exact customer/payor concentration is needs primary source validation from the 10-K.

No customer names are disclosed here. Viemed’s filings likely describe revenue concentration by payor, not by individual customer. Whether the latest 10-K says that Medicare/Medicaid accounts for a certain percentage of net revenue, or that no single commercial payor exceeds 10%, is needs primary source validation.

The following specific names are withheld because no filing was retrieved to confirm them as customers, payors, or referral partners. Do not treat any provider, insurer, or health system as a named Viemed customer until the EDGAR filing demonstrates it.

Remote patient monitoring platform for chronic respiratory care; recurring revenue from equipment rental + clinical support; profitable with positive FCF

Q2 2026 earnings expected Aug — sleep PAP patient adds +57% YoY converting to high-margin resupply revenue; FY2026 guidance $312-320M (17% growth); RPM reimbursement expansion under Medicare CPT codes

1. Ventilator unit economics — deck publishes ~$1,050/month reimbursement and ~17-month average length of stay [S2]. Lifetime revenue per vent patient ≈ $1,050 × 17 = $17,850. Annualized vent revenue at Q2-26 census of 12,635 patients ≈ 12,635 × $1,050 × 12 = $159M; cross-check against the P&L: Vent = 47% of Q2-26 revenue = $36.7M/quarter → $147M annualized (residual ~8% = blended rate + oxygen/airway-adjacent billing). The two reconcile within ~8%, validating the published unit economics.

1. Growth bridge — the bifurcation — Q2-26 revenue +$15.0M YoY ($63.1M → $78.1M). Vent (47% of mix) grew patients only +4% YoY (12,152 → 12,635), contributing ~$1.4M of the +$15.0M. The remaining ~90% of growth came from the diversified lines: PAP therapy patients +44% YoY (26,260 → 37,825), sleep resupply +46.7% YoY (25,246 → 37,035), and women's health (partial-year after the 7/1/25 Lehan's acquisition). The high-margin core is mature; the growth is lower-margin. [S1][S2]

1. Margin compression = the cost of diversification — gross margin 61.6% (FY23) → 59.4% (FY24) → 57.5% (FY25) → 58% (Q2-26); Adjusted EBITDA margin 23.5% (FY23) → 22.7% (FY25) → ~20.5% guided FY26 ($64–68M midpoint on $314–320M). The sleep/women's-health lines that drive 90% of growth carry structurally lower margin than ventilation, so each point of mix shift dilutes ~100–150bps of EBITDA margin. [S2]

1. Valuation / EV bridge — $371M market cap (8/7/26) − $10.7M cash + $6.4M LT debt = ~$366.7M EV. EV/FY26 revenue midpoint ($317M) = 1.16×; EV/FY26 Adjusted EBITDA midpoint ($66M) = 5.56×; EV/TTM FCF ($34.4M) = 10.7×; TTM net income $14.5M → ~25.6× P/E. [S2]

1. Cost-of-moat vs moat-defended — the recurring-revenue moat must be continuously re-fed: quarterly D&A $7.52M + SBC $2.03M (Q2-26) ≈ $38M/yr of maintenance spend against $147M/yr of vent revenue (≈26%) — the price of keeping the rental fleet current and the RT workforce compensated. [S2]

If w is the governmental-payor share of net revenue and r is a rate reduction on that governmental base, then:

Revenue impact = w × r

Example sensitivity, without asserting w:

These percentages are illustrative mathematical outputs. The actual government-payor share w is needs primary source validation and must be obtained from the 10-K before this becomes a load-bearing conclusion.